Life expectancy of at least months from most recent chemotherapy or immunotherapy treatment No comorbid conditions that would cause life expectancy of less than years Patients must have a life expectancy of >= weeks as determined clinically by the treating physician Life expectancy of at least weeks based on investigator estimate Have ECOG PS of or with an anticipated life expectancy of > months. Life expectancy < years Life expectancy of > months as defined by agreement of both the Chow et al. and TEACHH models SAFETY RUN-IN: Life expectancy of less than months Subject must have a life expectancy >= years PIKCA WILD TYPE COHORT (closed //): Life expectancy > months Patients with life expectancy >= weeks from time of CTL infusion Life expectancy of at least months in the judgment of the physician No prior primary or metastatic brain or meningeal tumors unless clinically and radiographically stable as well as off steroid therapy for at least months; a. Life expectancy ? weeks all (US); b. Life expectancy ? weeks; ? weeks superficial tumors (Canada); Patients with short life expectancy (less than months) due to comorbidity other than MDS or CMML Life expectancy ? mos Life expectancy ? years, as judged by the site investigator Life expectancy of less than months in the judgment of the study physician. Patients with a life expectancy < months from co-existing disease other than the leukemia or RAEB Life expectancy >= days Must have a life expectancy of at least years based on age and comorbidities but excluding diagnosis of breast cancer. Patients with a life expectancy of less than years No active or co-existing malignancy with life expectancy less than months No active or co-existing malignancy with life expectancy less than months Life expectancy >= weeks as judged by the treating physician. Life expectancy >= days Co-existing medical conditions with life expectancy < years Patients with a life expectancy of < months of enrollment from coexisting disease other than leukemia Life expectancy less than years; Patients must have life-expectancies > months to be included in the trial Life expectancy of at least years Life expectancy >= months at the time of study drug administration Minimum life expectancy of at least weeks. Expanded Safety Phase: Patients with any severe concomitant disease that may limit their life expectancy to less than years Life expectancy of ? months from the first OBP- treatment. Life expectancy < months (as estimated per diagnosis-specific graded prognostic assessment [ds-GPA]) Life expectancy of over months as determined by treating physician Life expectancy less than years Patients with short life expectancy (less than months) due to comorbidity other than MDS Life expectancy of >= weeks based on investigator estimate ECOG Grade - , with minimum life expectancy of at least months; Patients with life expectancy of =< months for reasons other than their underlying hematologic/oncologic disorder Presence of other comorbid illnesses with an estimated median life expectancy < years Subject has an ECOG Performance Status - and anticipated life expectancy > months prior to apheresis and > months prior to lymphodepletion. Life expectancy of greater than months (does not apply to pancreatic cancer population) Have at least month life expectancy Subjects must have a reasonable life expectancy of at least months Life expectancy =< months in the judgment of the treating clinician Life expectancy > weeks as judged by investigators Life expectancy of >= weeks (per treating investigators discretion) Life expectancy >= years (as determined by the treating physician) CAPMATINIB INCLUSION CRITERIA: Life expectancy >= weeks CERITINIB INCLUSION CRITERIA: Life expectancy >= weeks Patients with life expectancy of =< months for reasons other than their underlying hematologic/oncologic disorder No active or co-existing malignancy with life expectancy less than months Life expectancy >= weeks excluding their diagnosis of breast cancer Life expectancy with treatment should be >= months in the estimation of the treating physicians A life expectancy of at least weeks, even if requiring artificial ventilation. Life expectancy of at least years Life expectancy of >= years (yrs) Other serious medical conditions that may be expected to limit life expectancy to less than years (e.g., liver cirrhosis). At least month life expectancy Life expectancy > years Must have a life expectancy of at least years based on age and co-morbidities. Patients with life expectancy of =< months for reasons other than their underlying hematologic/oncologic disorder Life expectancy of greater than months to allow completion of study treatment and assessment of dose-limiting toxicity Patients with life expectancy of =< months for reasons other than their underlying hematologic/oncologic disorder A life expectancy of at least months with a Karnofsky performance status of at least Patients with life expectancy of =< months for reasons other than their underlying hematologic/oncologic disorder Minimum life expectancy of six weeks as determined by consenting professional No life expectancy restrictions will apply Life expectancy of >= years as determined by treating physician Patients with co-existing medical conditions with life expectancy < years Life expectancy reasonably adequate for evaluating the treatment effect A serious underlying medical condition other than NSCLC such that life expectancy is less than years. INCLUSION CRITERIA FOR CCT: minimum life expectancy of eight weeks life expectancy of less than months; Related to anticoagulant treatment: Life expectancy of at least days Stable clinical conditions and life expectancy > months Other life-threatening illness that is expected to impact life expectancy within years The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patients health and survival, than of the MCL with a life expectancy < years. Life expectancy of >= months in the attending physicians estimation Life expectancy estimate > months Life expectancy of > years per the clinical impression of the treating physician(s) Life expectancy > months as assessed by study physician TUMOR BIOPSY SEQUENCING: Life expectancy > months Life expectancy of >= years Minimum expected life expectancy > months < years life expectancy Life expectancy < years Life expectancy of at least months based on Investigators judgment. Life expectancy ? years Life expectancy of at least years, disregarding the diagnosis of cancer; ECOG Performance Status - and anticipated life expectancy > months. Patients with other active malignancies (no evidence of other cancer or life expectancy greater than years) are ineligible for this study Life expectancy ? years. Life expectancy >= months at the time of study drug administration Diagnosis of a coexisting medical condition which limits life expectancy to < years Life expectancy of at least years Life expectancy < days. Have ECOG PS of or with an anticipated life expectancy of > months. Patients must have an anticipated life expectancy > months. Patients must have a life expectancy of >= days Life expectancy < months as assessed by the treating physician Patient ? years of age. Patient life expectancy > months. Eastern cooperative group (ECOG) of or Life expectancy > years Life expectancy of at least years from the time of diagnosis, not considering the melanoma in question, as determined by the PI. Life expectancy of < months and/or has rapidly progressing disease Subject must be ? years of age. Life expectancy > weeks. Patients must have a life expectancy >= days Life expectancy >= months as determined by the treating physician Life expectancy > month Life expectancy < years Patients with life expectancy of =< months for reasons other than their underlying hematologic/oncologic disorder At least -month life expectancy. Life expectancy > years based on clinicians judgment Life expectancy less than month Patients with a life expectancy < months from co-existing disease other than the leukemia or RAEB Patients may have received therapy for other malignancies, as long as they have completed therapy at least months prior to study entry and be deemed to have a life expectancy of at least years with regard to that malignancy Life expectancy >= mos Other serious medical conditions that may be expected to limit life expectancy to less than years (e.g., liver cirrhosis). Life-expectancy based on comorbid conditions > years Patients must have a life expectancy of >= months and a Karnofsky performance status >= Life expectancy from a co-morbid illness > years Known history of or concomitant malignancy likely to affect life expectancy in the judgment of the investigator Life expectancy of at least years Any available standard line of therapy known to be life-prolonging or life-saving Life expectancy of at least weeks ( months) as determined by the treating physician. Patients with life expectancy of =< months for reasons other than their underlying hematologic/oncologic disorder or complications there from Anticipated life expectancy > months at the time of screening Anticipated life expectancy > months at the time of screening Life-expectancy of at least days Life expectancy of at least months in the judgment of the physician are eligible for any standard therapy known to be life prolonging or life saving History of second malignancies with life expectancy of < years or requirement of therapy that would confound study results. This does not include the following: Life expectancy >mo. Any co-morbid condition that poses a greater threat to the patients life expectancy than the recurrent myeloma No concurrent malignancy with a life expectancy of less than two years, or one that requires ongoing chemotherapeutic intervention at screening Subject has concurrent severe or uncontrolled medical disease or organ system dysfunction which, in the opinion of the Investigators, would limit life expectancy to < months. Anticipated life expectancy > months at the time of screening Not eligible for or declined transplantation or any standard therapy known to be life prolonging or life saving Patients life expectancy is >= years Patients with other active malignancies (no evidence of other cancer or life expectancy greater than years) are ineligible for this study Life expectancy of at least month Life expectancy of at least months in the judgment of the physician No co-existing medical conditions with life expectancy < years PATIENT EXCLUSION: Life expectancy of < month Patients must have a life expectancy of days Must have a life expectancy > days There are no restrictions related to performance status or life expectancy Patients with a life expectancy of =< months, as determined by their oncology providers, will be excluded Patients are eligible regardless of life expectancy PATIENTS ONLY: Physician-rated life expectancy of less than months Attending physician assessment of prognosis with expected life expectancy of > months Severe co-existing morbidities having a life expectancy of less than days No life expectancy restriction There are no restrictions related to performance status or life expectancy Has a life expectancy of months or longer; all cancer types are included There are no restrictions related to performance status and life expectancy Life expectancy >= days Have a life expectancy > months from the anticipated time of initiation of treatment Participants must have a life expectancy of years or more >= months life expectancy (physician estimate) No restrictions will be made based on life expectancy Life expectancy less than years EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Non-hematologic malignancy with a life expectancy of < years Suffering from a terminal illness with less than month life expectancy Terminal illness with less than month life expectancy Subjects with a life expectancy less than study duration; Life expectancy < months or Lansky score <% Life expectancy of >= years Life expectancy less than five years. Patients with anticipated life expectancy < months will be excluded Life expectancy < months (mo) Patients being considered for RALP and pelvic lymphadenectomy with life expectancy greater than years as determined by treating physician Life expectancy >= years There are no life expectancy restrictions Subject must have a life expectancy that exceeds the duration of the clinical trial Individuals with a short life expectancy (< years) There are no restrictions on life expectancy Life expectancy is not a consideration for protocol entry Life expectancy of >= months (as determined by treating physician) A referring physicians estimate of patient life expectancy must be between - months Patients with life expectancy of at least months and who are expected to be able to complete the full follow-up assessment in the protocol. Patients with distant metastatic disease (cM) or a life expectancy of less than years